Expanding Capabilities NanoImaging Services has recently expanded its service portfolio through the acquisition of Proteos, enabling it to offer comprehensive gene-to-structure workflows. This vertical integration positions the company as a one-stop solution provider for drug discovery clients seeking streamlined biomolecular analysis, creating opportunities to engage clients requiring end-to-end services.

Strong Industry Position As the industry leader with the most cryo-EM scientists and TEM microscopes in North America, NanoImaging Services provides a compelling value proposition for biotech and pharma companies looking for reliable, high-quality structural biology services. This established dominance can be leveraged to attract larger clients seeking proven expertise and advanced technology.

Recent Investment and Growth The company secured over $12 million in Series B1 funding and received growth equity from Ampersand Capital, highlighting strong investor confidence and growth potential. These financial inflows support ongoing expansion, modernization, and marketing efforts, making NanoImaging Services an attractive partner for potential clients investing in cutting-edge structural biology solutions.

New Service Launches The recent launch of cryo-transmission electron microscopy (cryo-TEM) services with full GMP compliance demonstrates the company’s dedication to biologics characterization and regulatory standards. This opens up new sales opportunities with biologics manufacturers and pharmaceutical companies needing compliant and precise imaging solutions.

Strategic Partnerships NanoImaging Services has established collaborations with leading biotech firms such as Cube Biotech and Cayman Chemical, indicating an active network of relationships within the biopharma ecosystem. These partnerships not only validate the company's technology but also create avenues to engage with innovative companies in vaccine development, nanoparticle research, and therapeutic discovery.